Home / Transcripts / Ipca Laboratories Limited (IPCALAB) · November 13, 2025

Ipca Laboratories Limited (IPCALAB) Earnings Call Transcript

November 13, 2025

National Stock Exchange of India IN Health Care Pharmaceuticals earnings 49 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the Ipca Laboratories earnings call for Q2 FY 2026, hosted by Dam Capital. I'd like to remind everyone that all participant lines are in listen-only mode, and after the presentation wraps up, you'll have a chance to ask questions. If you require any help during this conference call, just press star followed by zero on your touchtone phone to reach an operator. Please be aware that this conference is being recorded. At this point, I'll turn the call over to Mr. Nitin Agarwal. Thank you, and the floor is yours, sir.

Nitin Agarwal analyst
#2

Hello, and thanks. Good afternoon to all of you, and a very warm welcome to the Q2 FY 2026 earnings call for Ipca Laboratories, which Dam Capital Advisors Limited is hosting. Joining us today from Ipca Laboratories management are Mr. Ajit Kumar Jain, Managing Director, and Mr. Harish Kamath, Corporate Counsel and Company Secretary. I'll hand things over to Mr. Jain for his opening remarks, and after that we'll open the floor for questions. Please go ahead, sir.

Ajit Kumar Jain executive
#3

Thank you. I appreciate Nitin and DAM Capital for putting this call together. The hearing call today, along with the discussions and the answers provided, may contain some forward-looking statements that reflect our present business expectations. These need to be considered alongside the risks that the pharmaceutical business encounters. What we actually achieve financially could differ from the projections and perceptions. You are free to apply your own judgment regarding the information shared during this call. For Q2 FY 2026, the domestic formulation business delivered growth of roughly 8% during the quarter. Activity in the quarter was affected by GST rate rationalizations and the rate structure correction carried out in September 2025. Following that, we observed a very good recovery in the domestic market during October. As per IQVIA, Ipca's MAT September 2025 range held at approximately 16. In MAT September 2025, Ipca's market share rose to 2.8% from 2.3% in MAT September 2024. According to IQVIA data for the quarter, we outperformed the IPM in both the acute and chronic segments. Market growth overall during this period came in at about 7.8%, while Ipca grew roughly 11.6% in Q2. On the acute side, the market expanded by approximately 6.2%.

Ajit Kumar Jain executive
#4

Ipca grew at roughly 8.2%. In the chronic segment, the market expanded by about 10.3%, while Ipca's growth as tracked by IPM came in at approximately 14.2%. Our chronic and acute businesses have both posted stronger growth. All told, the chronic share of Ipca's total business rose from 34% last quarter to roughly 35% at present. For the market, that figure stands at about 40%. We keep raising our share of business coming from chronic now. Turning to export formulations, the quarter recorded roughly INR 493 crore versus INR 541 crore in the prior financial year. That works out to a decline of nearly 9% for the quarter. Across H1, the figure was about INR 941 crore compared with INR 937 crore in H1 2025 — essentially flat. We anticipate growth of approximately 8%-9% in generic formulations during H2 2026. On the API side, Q2 FY 2026 posted growth of about 28%, moving from INR 319 crore to roughly INR 408 crore, helped by improved business from Europe and Latin America. For the full current financial year, the API business is expected to grow by more than 14%-15%. In Q2 FY 2026, R&D spend climbed to about 3.91% of turnover, up from 2.7% in Q2 FY 2025.

Ajit Kumar Jain executive
#5

We’ll keep funding R&D at roughly 4% of turnover through this financial year as well. Turning to the margin picture, our standalone EBITDA margins came in at about 25.46% for Q2 FY 2026, compared with 22.89% in Q2 FY 2025 — an improvement of roughly 2.57%. For Q2 FY 2026, the consolidated EBITDA margin stands at approximately 21.68%, versus 19.1% in Q2 FY 2025. That consolidated EBITDA margin for the quarter also rose by close to 2.58%. Taking a broader view of the margin gains in Q2 of this financial year, we see that against our guidance of about a 20% consolidated margin, the margin should come in better by roughly 1% in the second half, and that improvement will be there. Now that I’ve laid out the headline numbers, I’d ask participants to go ahead with their questions.

Operator operator
#6

Thanks. We’ll start the Q&A portion now. If you’d like to ask something, you can press star and one on your touchstone cell phone. To take yourself out of the question queue, press star and two. We ask that participants use handsets when asking a question. Ladies and gentlemen, we’ll pause for a moment while the question queue assembles. Our first question comes from Sayan Mukherjee at Nomura Securities. Please go ahead.

Sayan Mukherjee analyst
#7

Hello there, good afternoon, and thanks for taking my question. I'd just like to hear your thoughts on the GST impact, if you're able to put a number on it, and also whether you could shed some light on the different therapy dynamics in India — how are those growing in the secondary market, please?

Ajit Kumar Jain executive
#8

So overall, the pain segment is our largest, and it keeps expanding at roughly 10%-11%. In Q2 we saw about 10% growth, and for H1 2026 it was 11%. Turning to cardiovascular, as we mentioned before, we went through a significant restructuring of that business in the first quarter of the current year, since we added two more divisions. That weighed on the first-quarter business. In the second quarter we're seeing a solid recovery — this business grew by roughly 11%. On a consolidated basis, for H1 the cardiovascular business grew around 10%. As for anti-malarials, they declined again this quarter. For H1 2026, this quarter, the decline was roughly 8%. Overall, the decline is about 2%. Antibacterials grew about 4% this quarter, and for the half year it's roughly 5%. In CNS, we had growth of about 18%, and for H1 it's around 14%. Cough and cold is recovering now — this quarter it grew by almost 17%, and for the first half it grew by about 18%. The pharma business grew by roughly 11% this quarter.

Ajit Kumar Jain executive
#9

Our urology segment came in at roughly 11% as well. That's even with a hit during September, since that month's growth was extremely weak on our end.

Sayan Mukherjee analyst
#10

Sir, how did that affect things, and what's your full-year guidance now for growth in India?

Ajit Kumar Jain executive
#11

So broadly speaking, our guidance was roughly 10%-11%, and we'll be right around that line here.

Sayan Mukherjee analyst
#12

All right, thank you, sir. The other thing I'd like to get your perspective on concerns Unichem. If you could just walk us through what we ought to anticipate. You mentioned synergies earlier — some have come through, and some are still to come. If you could speak to the timing and the size of those. What's your guidance on Unichem's EBITDA margin for this year or the next, please?

Ajit Kumar Jain executive
#13

So with Unichem, let's say we were discussing whatever cost reductions are needed on their shipping and logistics side, and that had already been completed. Their reductions in energy costs had already been completed too. In the last financial, it said that was done. On the business issues, the first one was that we should extend their product into the various markets. That work has begun. I think roughly 12 product dossiers are filed in the European market and other markets. That filing has started. That work, and following this filing, approval will probably take about one year to one and a half years. That's the timeline. Then we will begin extending their product businesses into the other markets. That work is going on. As for qualifying whatever API they purchase from outside, and where Ipca is one of the major sources, those qualification applications are already data, they are generated and filed with regulatory authorities. Once they, let's say, that's clear. So far, no sourcing has begun from Ipca. Once those approvals come, there may be some delay of maybe around six months to nine months. After that, probably from next financial year, some of our major APIs, we should start supplying to them once the regulatory approvals are in place.

Ajit Kumar Jain executive
#14

So that's the broader path we're on right now. Turning to Unichem's margins, the first quarter took a big hit largely from restructuring that took place in Europe — one of their manufacturing sites over there, we reached an agreement with the people involved and were in the process of shutting that facility down. That business moves over to their buddy. On an annual basis they were spending roughly EUR 3.5 million to EUR 4 million on that. That spending gets eliminated now. The manufacturing, all the sourcing, all the approvals are in hand. I believe normal business has already commenced at the buddy facility, which carries all of those approvals. Every customer, every regulatory approval, everything is in place. The Ireland facility is in the process of being closed. Those are the main changes involved. I think that cost landed on their first-quarter numbers. Regarding European Union penalties and such, that payment was made. I think because the EUR has moved against us, there was also that provision in Q1 for exchange differences of about INR 10 crore to INR 12 crore, and that hit their first quarter as well. The second quarter came in normal. They saw solid business growth in the U.S., roughly 12%.

Ajit Kumar Jain executive
#15

Europe has performed strongly for them as well. They’re generating EBITDA margins of roughly INR 60 crore, I believe, which works out to about 11% for the second quarter. Further gains will begin to materialize once the dossier filings that have already taken place lead to approvals from the different markets, and once they begin rolling out their product into additional markets. That benefit will still require some more time. Overall, I’d say their business margins should stay roughly in line with the second quarter. Meaningful improvement will likely come only after the various approvals we’re anticipating.

Sayan Mukherjee analyst
#16

So sir, what kind of levels could we reach — something like 15% to 20%? Once all those approvals and verification are done, what would it be then?

Ajit Kumar Jain executive
#17

The business also needs to mature, since these are business starts, so this will take time. My sense is that for margins to rise, it may take roughly one and a half to two years.

Sayan Mukherjee analyst
#18

All right. All right. Thanks, sir. I'll be part of that.

Operator operator
#19

Thanks. We'll take the next question from Anchil at Lotus Wealth. Your line is open.

Analyst analyst
#20

Hi there. Can you hear me okay?

Ajit Kumar Jain executive
#21

Yeah. Yeah.

Analyst analyst
#22

Yeah. Yeah. I was hoping to get a bit more clarity on the Unichem synergy. We're seeing R&D go up this quarter. If, say, Ipca's R&D sits at roughly INR 200 crore and Unichem's R&D is about INR 100 crore, then at the consolidated level that adds up to roughly INR 300 crore, is that right? Looking ahead to next year, is it fair to say this INR 300 crore expense could come down to somewhere around INR 150 crore or INR 200 crore?

Ajit Kumar Jain executive
#23

No, that cost-cutting won't materialize, since Unichem still has substantial work ahead when it comes to, say, expanding their dossiers across the different markets. In many locations, repeat bioequivalence studies must be conducted so filings can be made in other markets such as Australia, New Zealand, Canada — all of those markets — plus filings for Europe and so on. Those bioequivalence studies and the like are needed. In some cases trade dress has to be matched, because the tablet colors may differ in certain places and the shapes and sizes vary as well. Quite a bit of that type of work, incremental work, has to be carried out so the product portfolio can be aligned and those sorts of approvals obtained. As a matter of fact, those expenses will stay. What we've done away with is that the two teams won't be working on a shared product. Duplication will be gone. When it comes to the work itself, that cost in fact has already gone up and will continue sitting at that level, because plenty of incremental work is needed to achieve better fructification of their product range from other markets.

Analyst analyst
#24

Thank you, sir. And then regarding the NDA synergies — suppose Unichem already holds an approved NDA; is it possible for Ipca to leverage that same molecule NDA and realize any synergy in that area?

Ajit Kumar Jain executive
#25

To put it another way, suppose Unichem handles the marketing of Ipca items. So if Unichem is manufacturing their NDA, they'll keep manufacturing it. That area won't be touched by Ipca. The sole change is that future development will hinge entirely on this: should Unichem possess the API, then Unichem will take that product forward. Should Ipca hold the API, then Ipca will be the one to develop it. There won't be any shared product development happening at the two locations. Still, each team will keep working on new product development, meaning both teams will operate within their own respective ranges. Yeah.

Analyst analyst
#26

All right, sir, got it. Just one final item. I was hoping you could walk me through what the 505(b)(2) pipeline looks like at Ipca, and also at Unichem.

Ajit Kumar Jain executive
#27

There's nothing like that in our pipeline.

Analyst analyst
#28

All right, sir, thank you very much.

Operator operator
#29

Thanks. Our next question comes from Prashad at Motilal Oswal Financial Services. Go ahead, please.

Analyst analyst
#30

I appreciate the chance to address this. Regarding the generic export side, you mentioned guidance of 8%-9% expansion in the back half of the year — what exactly will be behind that? Are there specific product approvals or momentum we can point to? Since for generics, the first half came in fairly flat.

Ajit Kumar Jain executive
#31

For the first half, it was essentially driven by a single product, since the market held fairly high inventory levels and none of that product was being manufactured. Apart from that, if I look at the European business from a ranges standpoint and so on, it performed well. Taking into account the orders we currently have, our customer conversations, and what we expect for the business, we believe we can achieve roughly 8%-9% growth in generics during H2 2026. Yeah.

Analyst analyst
#32

Understood. And in a similar vein, for branded exports too — I mean, the first half has been fairly weak once again.

Ajit Kumar Jain executive
#33

In the first quarter, we saw solid growth. Keep in mind that's just Q2, and there can be quarter-to-quarter variation. On a full financial year basis, that business should also deliver roughly 9%-10% growth. In a business like this, you always get some fluctuation from quarter to quarter, particularly in ROW markets and so on. But overall, for the year, I have no doubt that sort of growth will not be achieved.

Analyst analyst
#34

Understood. Last thing from me, then, on the API front: this quarter came in fairly solid, yet for the full year we're guiding toward a somewhat slower growth rate. Should we read that as some of the businesses we had being ones that won't repeat in the quarters that follow?

Ajit Kumar Jain executive
#35

Right. A number of our APIs that we were selling but where volumes were low — certain of those have gone to customers in Europe. I think there was bulk procurement there for their businesses and so on, and that also came at higher margins. That business will carry on, but there may not be buying in the third quarter to that same extent. Once they've consumed it, they'll come back again. Taking all of that into account, for the API business overall, the guidance we've provided is growth of roughly 14%-15% in total.

Analyst analyst
#36

And finally, if I could, how is the U.S. business progressing on Ipca's side?

Ajit Kumar Jain executive
#37

Broadly speaking, business is performing quite well. I believe we mentioned last quarter as well that the current activity underway is translating into roughly INR 14 crores to INR 15 crores. I think we've shipped about six products there, and roughly five to six products are currently in manufacturing. Once those products go out, the business will probably begin in the fourth quarter of the current year, or perhaps some business maturing could take a bit longer. We hadn't been present in the market for such a long stretch. It's taking some time to make up for that kind of business. That's why, on the whole, we're more conservative on that front.

Analyst analyst
#38

Understood. So this 2KOM, at INR 14 crores to INR 15 crores, is that what you're producing?

Harish Kamath executive
#39

So for H1 as a whole, we've brought in roughly INR 55 crores.

Ajit Kumar Jain executive
#40

Right.

Analyst analyst
#41

Understood, sir. Thanks.

Ajit Kumar Jain executive
#42

Right.

Analyst analyst
#43

That is all, sir.

Operator operator
#44

Thanks. Our next question comes from Rajakumar at RK Industry. Your line is open.

Analyst analyst
#45

Yes, good evening, sir, and thank you for the chance to ask. Sir, my question concerns the cash position at Unichem. Once this penalty has been paid, would Unichem require any cash infusion?

Ajit Kumar Jain executive
#46

No, cash isn't something Unichem needs. As a matter of fact, they're sitting on surplus at the moment too. They generated cash from the business in the current quarter as well, and that will keep happening. I don't believe so. Their Jogeshwari land has already been sold by us, and I think the total proceeds from it, even after this entire payment, will still leave Unichem with some surplus. Even once tax is paid, a surplus will remain. Yeah.

Analyst analyst
#47

All right. Has that cash from the Jogeshwari sale already been realized?

Ajit Kumar Jain executive
#48

Jogeshwari sales — yes, the money does come in. Yeah.

Analyst analyst
#49

All right. Since we're currently in the.

Ajit Kumar Jain executive
#50

We delivered on that in Q3.

Analyst analyst
#51

My apologies — this is the second quarter, correct?

Harish Kamath executive
#52

The transaction took place in October. It will be reflected in the third quarter.

Ajit Kumar Jain executive
#53

The third quarter — that's exactly what I said.

Analyst analyst
#54

Right. Right. Understood. Understood. Sir, and also, although Unichem has a very large inventory situation, when you compare it with the business between Ipca and Unichem, it's similar. Their inventory levels at Unichem are very high relative to Ipca.

Ajit Kumar Jain executive
#55

Unichem's operations are essentially the U.S. operation. Roughly 80% of it is U.S. business. Their cycle requires them to hold about three months of inventory in the U.S., plus transit inventories and that sort of thing. Since many of their products also come from their own API basket, there are API inventories as well. We're also working on cutting back that kind of inventory. You'll see that this quarter, we brought down total inventory across the system by roughly INR 150 crore. Yeah.

Analyst analyst
#56

Alright. Sir, finally, could you say something about? Yeah. Yeah. Finally, would you be able to remark on your other listed subsidiary, such as Unichem Lab? In that case too, there was some fairly notable worsening in how they performed.

Ajit Kumar Jain executive
#57

So, for instance, our lab does a substantial amount of P2P business. With the GST rationalizations and all of that, many customers told us, "Don't manufacture in September, because once the price changes, that's when they want production—they can't take batches and hold them." I believe that business was affected, and I think they had some rejections of some kind. That impact came to roughly INR 5 crore to INR 7 crore on their overall number. That has hurt the business. Yeah.

Analyst analyst
#58

Alright, thank you, sir.

Ajit Kumar Jain executive
#59

Beyond that, the critical care segment they're developing, plus the animal healthcare operation they're also growing — that trajectory is progressing exactly as expected. Yeah.

Analyst analyst
#60

That final study is having an effect on Lyka, isn't that right?

Ajit Kumar Jain executive
#61

Right.

Analyst analyst
#62

Understood. Many thanks, sir.

Operator operator
#63

Thanks. Just a quick note for everyone on the line — you can hit star and one whenever you'd like to ask something. Our next question comes from Kunal at Axis Capital. Go right ahead.

Analyst analyst
#64

Hello, and good evening, sir. Sir, my question concerns R&D. Sir, you currently have roughly 7 biosimilar projects in the pipeline, and 3 of those are anticipated to enter clinical trials next year. I would note that R&D has risen somewhat this year. Should we expect that next year the increase in R&D will be even steeper than that?

Ajit Kumar Jain executive
#65

My sense is that, on the whole, R&D spending for this financial year will stay at roughly 4% of turnover, since a great deal of filing work and bioequivalence studies — plus our filings across various markets — are underway, and the pipeline is also getting much stronger. Those costs are rising as well. On top of that, there are the biosimilar expenses. Once clinical trials get going, that will add further cost. That 4% could rise to about 4.5% or 4.75% in the next financial year.

Analyst analyst
#66

Understood, sir. Sir, second, looking at your OpEx, R&D included, it has risen by just mid-single digits. Given that R&D has climbed considerably, is that due to some costs being deferred, or have you carried out some cost optimization? If you could shed some light on that.

Ajit Kumar Jain executive
#67

Basically, every other cost is staying under control. On the manufacturing overhead side, take fuel cost — that's down. My power cost rose only 1%, since we've installed quite a few renewable power projects. Those savings are starting to come through. On the whole, aside from testing cost, which went up, the remaining costs are largely unchanged. Manufacturing cost hasn't escalated much. Marketing cost climbed roughly 6%-7% during this quarter.

Analyst analyst
#68

Understood, sir. So is it that you've kind of halted growing the sales force, since during the last 2 years you were adding to it? That was also somewhat weighing on your P&L. At this point it's more of a steady-state growth figure. Should we assume that going forward as well?

Ajit Kumar Jain executive
#69

So this year as well, we've grown the field force. If you look at the overall picture, we now have close to 7,000 medical reps. During the current financial year, two additional cardiac divisions were brought in. Going forward, we'll be adding one more division in cosmeto-dermatology. Some of those expenses were already incurred, and more are likely to come. Also, a division called FLEXICARE was introduced to build out our equity in, say, pain management, since ortho is an area where we're very strong and hold leadership. We only had pain products, so we've launched a range of products there. That division started last year. It's still running at a loss. In time to come, that productivity will build up as well. We have close to 7,000 people right now. The additions won't be significant. Perhaps about 400 people to 500 people can be brought in each year. Beyond that figure, no further addition will happen over the coming two to three years.

Analyst analyst
#70

Understood, sir. One final question, if that's alright. Sir, it concerns margins. This quarter, growth came from API and the subsidiaries — the top 10 groups — which I take to be businesses with lower gross margins, whereas India and Branded were a bit softer. Even so, the gross margin is quite robust. I'd just like to grasp how you've managed to achieve 69%-70% gross margin.

Ajit Kumar Jain executive
#71

If you take a look at the numbers for the current quarter, on the whole, the top line, let's say, has risen by roughly 7%. Meanwhile, material cost has come down by a reduction of nearly 3%-4%, something in that range, on material cost. What we're seeing is that there's no rise in material cost as such, meaning procurement cost. Because our product mix is getting better — let's say my chronic product mix is getting better, my other product mix is getting better, where margins are high for us — that is feeding through into the overall margin. Then also on the API side, some businesses have begun to come through, and those sit at a higher margin level too. That margin has improved as well. All of that has produced an improvement of almost around EBITDA margin. Despite lower growth in the quarter, we've had an improvement of almost around 2.57% in standalone EBITDA margin, going from 22.89% to almost around 25.46%. Consolidated margin for the quarter has likewise improved to around 21.68% from 19.1%. Broadly speaking, it's mainly Ipca's margins that are driving this here. That trend will carry on. The trend will carry on.

Analyst analyst
#72

Okay, so your point is that the 25.2% standalone EBITDA margin still has more room to grow?

Ajit Kumar Jain executive
#73

Margins are getting better, I'd say. This quarter is a peak one. In the next quarter, certain businesses — the domestic ones — come down. In the fourth quarter, the domestic business is low. It depends on the mix, but I'd say margins will keep improving relative to last financial year.

Analyst analyst
#74

Understood — thank you, and best wishes.

Operator operator
#75

Thanks. Just a quick reminder for everyone: to ask a question, press star and one. Our next question comes from Dharmil Shah at Telmanas Capital. Please go ahead.

Dharmil Shah analyst
#76

Hello, and thanks for the chance to ask. My questions focus mostly on Unichem and its generic business. We continue to hear from the other Indian generic companies about price erosion in the U.S. market. For us, what has the trend been — what do our monthly reads show over the last 2 to 3 years when it comes to price erosion? What is the situation at present? How do you expect it to play out over the next 2 to 3 years?

Harish Kamath executive
#77

Back on our Q1 phone call, we mentioned that Unichem had been losing share in some of its products. Lower pricing on that product plus rising competition are also behind that. At the same time, they've picked up share in a handful of other products. Turning that into business is going to take a while. Looking ahead, we're confident that two to three new products will also be added annually. On a standalone basis, their U.S. business ought to grow roughly 8%-10%.

Dharmil Shah analyst
#78

Got it. What's the—

Ajit Kumar Jain executive
#79

On top of that, they’ll be marketing Ipca products as well.

Dharmil Shah analyst
#80

Got it. So when you take into account all the factors you're weighing, that points to growth of 8%-10%.

Harish Kamath executive
#81

You've got it right. Yeah. Growth this year came in a bit lower since, like I mentioned, they gave up some market share in two of their biggest products. That's the reason. Nothing else.

Dharmil Shah analyst
#82

Why did we lose that market? Is price the only factor behind it?

Ajit Kumar Jain executive
#83

Competition ramped up, and lower prices were being quoted, and they captured some market share.

Dharmil Shah analyst
#84

Got it. Would you say it's closer to a tendering-style business for us, where the tenders come up each year?

Analyst analyst
#85

This isn’t really a tendering-type business. Whenever market share becomes concentrated among just a few companies, other players also enter the business. That happens. Whatever ground they’ve lost, they might regain in the next cycle. That’s an ordinary occurrence in the generic business.

Dharmil Shah analyst
#86

Got it. Do you figure that price erosion will keep going, maybe, unless you're able to put a number on it — single digit, lower single digit?

Harish Kamath executive
#87

It varies from one product to another. Should competition rise, then prices will come down. If not, there's also a possibility that pricing could go up. That's just how the cycle works. No one is able to predict it accurately. Everything hinges on the competitive situation. How many new entrants show up in that molecule?

Dharmil Shah analyst
#88

Got it. You brought up.

Ajit Kumar Jain executive
#89

Right now, we aren't observing shortages of any kind in the U.S. market. Pricing pressures are certainly present. One-time buying opportunities are somewhat lower at the moment. Yeah, that used to mean more margins. That business opportunity, we're not seeing it to that degree at present.

Dharmil Shah analyst
#90

Got it. So that’s 8%-10% growth for the U.S. business. But what are you expecting across the rest of the market? I mean, the other geographies you said you’d be marketing in.

Harish Kamath executive
#91

So that's what we've been working on. We've begun submitting Unichem dossiers in the remaining markets. Registering a dossier generally runs somewhere from 12 to 18 months. After those dossiers get registered, we'll be bringing their product into a great many other markets where they aren't currently present: Europe, Australia, New Zealand, Canada, as well as the ROW market. That effort is underway. Since regulators are involved, this whole set of processes takes a period of two to three years.

Dharmil Shah analyst
#92

Got it. Yeah, I realize securing the approvals and launching the marketing of the new products is a really lengthy process. To get a bit more clarity on that point, right now the U.S. share of the Unichem business accounts for roughly 60%-65% of U.S. revenue.

Harish Kamath executive
#93

You could put it at 70%.

Dharmil Shah analyst
#94

Yeah, so let's assume that with the new products and the newer geographies, where do you see the U.S. contribution dropping to, maybe in the next 3 to 5 years?

Harish Kamath executive
#95

It’s going to decline gradually as well. Once registration is in place, you begin marketing, and then you build share. That’s a slow, step-by-step process. After it gets going, you’ll keep expanding each quarter. Only we can say that. It’s a gradual process. You shouldn’t expect anything to happen dramatically over a shorter stretch of time.

Dharmil Shah analyst
#96

Got it. Over the past 3 quarters, gross margins have come in at roughly 54% to 55%. Does that stem entirely from the market share loss you referenced for the key products, or is there another factor at play?

Harish Kamath executive
#97

Right. The main reason their gross margin has declined is that market share loss.

Dharmil Shah analyst
#98

Understood. All right, then this has no connection at all to the contract manufacturing business, correct?

Harish Kamath executive
#99

No, no, no — that's not it at all. Sadly, the categories where they gave up share were big on volume too. With that drop in volume, their overhead recovery has taken a hit as well.

Dharmil Shah analyst
#100

Got it. At this moment, considering how much capacity we've brought on in Unichem, in population as well as.

Operator operator
#101

If you have any additional questions afterward, please get in line. Thanks. Our following question comes from Surya Narayan Patra at Phillip Capital. You may proceed.

Surya Patra analyst
#102

Yes. Thank you for the chance, sir. First, on growth: ours has been fairly muted lately, clearly because of the underperformance on the export side. Yet Europe as a market has turned out to be among the strongest performers for many of the bigger players too. We've seen some price appreciation there that has been helping people. Even though Europe is one of our biggest markets, growth has not been supported in any way. What might be affecting our growth in Europe?

Harish Kamath executive
#103

No — Mr. Jain already covered that; it comes down to one single product. If you set that product aside, sales across every other product are good. The products posting good sales carried better margins. Margin was not affected. Apart from that one particular product, all is well. On top of that, we are undertaking many other initiatives to grow our European footprint. A number of products are registered, and we are also securing registration in Germany. Going forward, we shall take part in tenders there as well. A subsidiary has already been incorporated. Europe is a focus market for us, and we are hopeful that our growth in the European market should be good going ahead. In addition, we have begun filing Unichem dossiers in the European market. The basket will also increase.

Surya Patra analyst
#104

All right, all right. So up to now, we haven't been seeing that cross-selling benefit. Is that what you meant to say?

Harish Kamath executive
#105

Nope, nothing at all. Up to this point, zero.

Surya Patra analyst
#106

Alright.

Harish Kamath executive
#107

There are just 2 dossiers that are registered at this point, and those are the ones we're currently taking to market — we've begun conversations with customers.

Surya Patra analyst
#108

Okay. Regarding sales in the domestic market, we have consistently been growing at a large margin ahead of the IPM. Now we have more or less begun tracking close to the pace of the market. A bit better, though. Looking ahead, see, clearly two trends are emerging for the domestic market. First is some moderation in growth generally. That is one. And second, a larger growth trigger that is coming, namely GLP. Given these two aspects, what is our expectation, and what is our preparedness and thinking regarding the GLP opportunity as well? Beyond that, how should one think about overall domestic growth for Ipca?

Harish Kamath executive
#109

We feel very sure that our growth is going to exceed the market's growth. On that point, there's zero doubt. We're also working on the therapies where growth previously wasn't good, such as cardiac and all. Of that, we have now begun to see the result. We are now outperforming the market as far as cardiac therapy is concerned as well. We are very confident our growth will be better than the market growth.

Surya Patra analyst
#110

All right, regarding GLP, is there anything you’re able to share, sir? How prepared are you for the point when it’s available in the market?

Ajit Kumar Jain executive
#111

When it comes to GLP, we didn't carry out R&D of that type. We had no E. coli-based R&D. We're already in the process of establishing the facility for R&D — biotech R&D for products based on E. coli. That will take time. In the current phase of the product, we won't be in that kind of race. Whenever the next phase of the product comes, we'll be there. We're already synthesizing the clones, and other things are already underway. On the market opportunities side, we're also looking at purchasing the product from other manufacturers and so on. We're evaluating that opportunity. Nothing has been finalized as of right now, but yes, that process is ongoing.

Surya Patra analyst
#112

Alright, just one last thing from me, sir. Actually, could you speak about your R&D pipeline — whether it's aimed at the US market or at whichever emerging market opportunities? Look, what's the main focus of R&D right now, and which direction are we thinking at this point?

Ajit Kumar Jain executive
#113

R&D right now has capacity to file roughly 30 to 35 products. It's going to be the same product. Each filing counts as one number across the different markets. That's about where current capacity sits. Before, we weren't, let's say, using it to the fullest, since we weren't present in the U.S. market. U.S. filings have begun as well. I believe 2 filings have already gone in, and they have a pipeline of about 5 to 6 products. We've also sped up a lot of development work now for Europe, Australia, New Zealand, and the Canada market. That's underway too. You'll see R&D cost climbing as well, not just on the Biotech side but also on biofluences and foundation development. We're building a very strong pipeline for future growth.

Surya Patra analyst
#114

Alright. Yes, thanks, sir. Wishing you the very best.

Operator operator
#115

Thanks. Our next follow-up comes from Sayan Mukherjee at Nomura Securities. Your line is open.

Sayan Mukherjee analyst
#116

Yes, I appreciate the follow-up. I’ll pick up on that question about filings. You’ve already submitted two, and another five to six are in development. Could you walk us through it from a somewhat longer-term view — say across the coming five years — how we ought to think about the U.S. business when it comes to filing, what those files are like, the products involved, and how should we view the U.S. business scaling up over that same five-year stretch?

Ajit Kumar Jain executive
#117

We're not a business that's going to do a great deal of filing on the back of someone else's API. Broadly speaking, whatever sits in our pipeline — whether it's the current one or what we expect will be in it — only those products are what we develop and file for the U.S. market. Relative to other firms, our filings will by and large probably stay low. Everything hinges on our API capacity, since in the end, without API you can't be a long-term player, because you're all reliant on the price that other parties set, and that constrains your capacity to compete in the market and so forth. That's the business philosophy, and that philosophy is going to stay for longer terms.

Sayan Mukherjee analyst
#118

If I ask you how many, then you'd be creating new APIs for this, correct?

Ajit Kumar Jain executive
#119

Yeah, yeah.

Sayan Mukherjee analyst
#120

Okay, so with these APIs — is there a number attached to them? I mean, how should we be thinking about that category of products?

Ajit Kumar Jain executive
#121

At present, we can handle roughly five to six API developments in-house. So only those programs will be worked on internally, on the foundation side. Certain APIs could be outsourced and filed as well, though that won't amount to a significant number. When an API makes up a very small share of the total product cost, we might outsource it, or perhaps it's a general type of API that many products are being made from. In those cases, we may decide not to take up such APIs. That's the overall approach.

Sayan Mukherjee analyst
#122

Alright. Alright.

Operator operator
#123

Thanks. Our next question comes from Rajak Kumar at Ajay Invest. Go right ahead.

Rajak Kumar analyst
#124

Yes, thanks for that follow-up. On the first question, could you say something about the monetization opportunity in relation to the tech transfer deal you completed with BioSimilar in Puerto Rico?

Ajit Kumar Jain executive
#125

So let's say it's one of the older products and it's still very relevant. The U.S. government business is bigger too, and the party wanted to take, let's say, the technology for your drug substance as well as the drug product, both. We have a system of milestone-based payments and royalties. At the same time, that party is an expert on NDAs and does the filing. He's a regulatory consultant to so many companies on biosimilar development and all. Collaborating with him will also help us in your qualification of that plant from U.S. FDA and other markets and all. His assistance would be available to us because he's already consulting a large number of companies in India, China, and Europe also on biosimilar kind of development and all. Very experienced person. On that particular product, he will also, let's say, his focus more and more is likely to be the government business and other. He will also do some private business. Simultaneously, we will also be participating in clinical trials with him. Both the facilities will have approval. That is the kind of working we are doing. On that, we will also get the market share in the U.S. From whatever business he does, almost around 25% is the market share which will come to us on that particular.

Ajit Kumar Jain executive
#126

That's the general understanding that exists between us and the other party. Yeah.

Rajak Kumar analyst
#127

All right. Is there no way to monetize this part of the finances as far as the deal is concerned?

Ajit Kumar Jain executive
#128

No. Technology transfer isn't really what we're focused on. What we're after is U.S. approvals and that individual's experience, since he has, in a very hands-on way, worked with every company in India — practically all of them — as a consultant.

Rajak Kumar analyst
#129

All right, I understand.

Ajit Kumar Jain executive
#130

Extremely valuable expertise—that’s something we aimed to put to use as well. Our goal isn’t to remain in the business of moving those technologies over and overseeing them. Those technologies are going to serve us in strengthening our pipeline.

Rajak Kumar analyst
#131

Understood, sir. The second point concerns clarifying the margin guidance. During the previous quarter, you stated that your margin would decline by 25 basis points. At present, you are saying it looks better thanks to performance. You are raising your margin by 100 basis points. Is that the correct understanding?

Ajit Kumar Jain executive
#132

Right, so the mix of products is getting better, and that's what's driving the improved margin. That's the basis for the guidance we're giving. Around that period, Unichem's first-quarter result wasn't all that strong. Their business is picking up too. The hit we saw in the first quarter probably won't be there in the third and fourth quarters. That's been factored in as well when we set the margin. Ipca's margins are getting better. Unichem's performance is improving too, as far as EBITDA goes, compared with the first quarter. Overall, on Ipca's margins, we've seen better margins this quarter. So taking all of that into account, we're raising the overall margin guidance.

Rajak Kumar analyst
#133

Alright, thank you, sir.

Operator operator
#134

Thank you. Ladies and gentlemen, that was the final question for today. The question and answer session has now concluded. At this point, I'd like to turn the conference back to management for closing remarks.

Harish Kamath executive
#135

No, madam, you may go ahead and close out the conference. I don't believe there are any further questions, so we'll wrap it up. Thank you. Thanks to all of you for joining this conference. Thank you.

Operator operator
#136

Thanks. On behalf of Ipca Laboratories and Dam Capital, that brings this conference to a close. We appreciate you being with us, and you can go ahead and disconnect your lines now.

Harish Kamath executive
#137

Much appreciated.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ipca Laboratories Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ipca Laboratories Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.